ARGX
argenx SE
There isn't enough reported data to score ARGX yet.
ARGX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ARGX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ARGX PE Valuation
ARGX has no meaningful PE right now: it lost money over the past year.
ARGX Forward outlook
There aren't enough analyst estimates for ARGX to show an outlook.
ARGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2021 | -$7.99 | +$4.95 |
| Q2 2021 | -$6.52 | +$2.10 |
| Q4 2020 | -$12.94 | -$8.25 |
| Q2 2020 | -$8.62 | -$5.78 |
| Q4 2019 | -$4.69 | -$2.48 |
| Q4 2018 | -$2.21 | -$0.94 |
ARGX lost $7.99 per share over the past year, a bigger loss than the year before.
ARGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2021 | $497.3M | +3089% |
| Q2 2021 | $470.4M | +1791% |
| Q4 2020 | $15.6M | -47% |
| Q2 2020 | $24.9M | -49% |
| Q4 2019 | $29.2M | +635% |
| Q2 2019 | $48.4M | +143% |
| Q4 2018 | $4M | -90% |
| Q4 2017 | $40.5M | +275% |
ARGX's revenue has grown year over year for four quarters in a row: $497M last quarter, up 1605% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2021 | -70% | +403 points |
| Q2 2021 | 20% | +145 points |
| Q4 2020 | -1541% | +39 points |
| Q2 2020 | -900% | -758 points |
| Q4 2019 | -473% | -410 points |
| Q2 2019 | -125% | +20 points |
| Q4 2018 | -1581% | -1475 points |
| Q2 2018 | -142% | -4.6 points |
ARGX's operating margin was −70% last quarter, up 403 points from the same quarter a year ago.
ARGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2021 | -$610.4M | -$376.4M |
| Q2 2021 | -$227.5M | -$75.6M |
| Q4 2020 | -$234M | -$128.8M |
| Q2 2020 | -$151.8M | -160% |
| Q4 2019 | -$105.2M | -$75.7M |
| Q2 2019 | $253M | +$283.9M |
| Q4 2018 | -$29.5M | +$11.5M |
| Q4 2017 | -$41M | -$28.2M |
ARGX has burned cash in most quarters: −$1.2B over the past year, against $87M the year before.
ARGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +437K shares |
| 1 year | +32% | +12.5M shares |
| 3 years | +225% | +35.4M shares |
ARGX has 51M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2016 | — |
| Q2 2016 | — |
| Q4 2015 | — |
| Q2 2015 | — |
| Q4 2014 | — |
| Q2 2014 | — |
| Q4 2013 | — |
| Q2 2013 | — |
ARGX Net Leverage
ARGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ARGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.4 | Neutral |
| Stochastic | 51.3 | Neutral |
ARGX's weekly RSI is 58 (neutral) and its Stochastic is 51 (neutral).
ARGX PE vs Healthcare Sector
ARGX has no meaningful PE right now: it lost money over the past year.
ARGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $899.8 | 9.1% above |
| 20 week MA | $921.8 | 6.5% above |
| 50 week MA | $855.0 | 15% above |
| 100 week MA | $759.7 | 29% above |
| 200 week MA | $602.7 | 63% above |
ARGX is in an uptrend: it's above all five of its weekly moving averages, and 63% above its 200-week average.
ARGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $160.8 | $299.5 | +86% |
| 2021 | $299.5 | $350.0 | +17% |
| 2022 | $350.0 | $377.3 | +7.8% |
| 2023 | $377.3 | $380.4 | +0.8% |
| 2024 | $380.4 | $626.3 | +65% |
| 2025 | $626.3 | $844.9 | +35% |
| 2026 YTD | $844.9 | $981.3 | +16% |
ARGX has finished every year since 2020 higher, and it's up 16% so far in 2026.